Table 1. Limitations of current licensed pneumococcal vaccines
Figure 1. Upper respiratory bacterial-viral coinfection and Spn pathogenesis.
Figure 2. Protein antigen specific CD4 T cells and Spn clearance.
Table 2. Characteristic components of Spn Protein Vaccine Candidates
Table 3. Pneumococcal protein vaccine candidate evaluated in clinical trials
Table 4 Vulnerable populations, risk factors for Spn infections and immune system
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
